Histogenics Corp. (HSGX) Shares Up 7.5% After Analyst Upgrade
Histogenics Corp. (NASDAQ:HSGX) shares shot up 7.5% during mid-day trading on Tuesday after Needham & Company raised their price target on the stock from $8.00 to $11.00. Needham & Company currently has a buy rating on the stock. Histogenics Corp. traded as high as $3.32 and last traded at $3.30, with a volume of 59,492 shares trading hands. The stock had previously closed at $3.07.
Several other research analysts have also issued reports on HSGX. William Blair lowered shares of Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 7th. Zacks Investment Research raised shares of Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research note on Friday, August 26th. Finally, BTIG Research raised shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 target price on the stock in a research note on Thursday, August 11th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $7.65.
A hedge fund recently raised its stake in Histogenics Corp. stock. Sabby Management LLC boosted its position in shares of Histogenics Corp. (NASDAQ:HSGX) by 28.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 150,630 shares of the company’s stock after buying an additional 32,965 shares during the period. Sabby Management LLC owned 1.14% of Histogenics Corp. worth $345,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 38.63% of the company’s stock.
The stock’s market cap is $42.33 million. The firm’s 50 day moving average price is $2.94 and its 200 day moving average price is $2.30.
Histogenics Corp. (NASDAQ:HSGX) last issued its earnings results on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same period in the previous year, the business earned ($0.58) earnings per share. Analysts predict that Histogenics Corp. will post ($2.11) earnings per share for the current fiscal year.
About Histogenics Corp.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.